Chengdu Kanghong Pharmaceutical's (SHE:002773) unit, Chengdu Kanghong Biotechnology, received approval from China's National Medical Products Administration for the clinical trial of KH812 injection, according to a Shenzhen bourse filing on Wednesday.
The drug will be tested as a treatment for neovascular (wet) age-related macular degeneration.